Niezgoda, Adam
Biegański, Grzegorz
Wachowiak, Jacek
Czarnota, Jarosław
Siemionow, Krzysztof
Heydemann, Ahlke
Ziemiecka, Anna
Sikorska, Maria H.
Bożyk, Katarzyna
Siemionow, Maria http://orcid.org/0000-0001-6372-6122
Article History
Received: 11 September 2023
Accepted: 20 October 2023
First Online: 24 November 2023
Declarations
:
: MS is CMO and shareholder of Dystrogen Therapeutics Corp. the company that holds a license for DT-DEC01 therapy. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). The author declares a potential conflict of interest. KS is CEO and shareholder of Dystrogen Therapeutics Corp. AH is the adviser to Dystrogen Therapeutics Corp. The authors declare a potential conflict of interest. AN, GB, JW and JC received fees for work related to this study. AZ, MHS and KB are Dystrogen Therapeutics Corp. employees.
: The study was conducted according to the guidelines of the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines. The study protocol (DT-DEC01-DMD) was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval No. 46/2019).
: Informed consent was obtained from all subjects involved in the study.